Pseudo-sle syndromeM32.0
Synonym(s)
LLS; lupus erythematosus-like syndrome; Lupus erythematosus visceralis syndrome; lupus-like syndrome; Pseudo-LE Syndrome
DefinitionThis section has been translated automatically.
A clinical picture reminiscent of systemic lupus erythematosus and fulfilling the criteria of the American College of Rheumatology (ACR - Early American Rheumatism Association/ARA) for systemic lupus erythematosus, which occurs after taking certain drugs.
EtiopathogenesisThis section has been translated automatically.
Mainly triggered by hydralazine, hydantoin compounds, procainamide, sulfonamides, also Venopyronum. Pseudo-SLE syndrome or lupus-like syndrome occurs under therapy with all approved TNF-alpha antagonists with an estimated incidence of 0.2% (see Biologics).
Clinical featuresThis section has been translated automatically.
Typical skin lesions of systemic lupus erythematosus, frequent fever episodes, occurrence of DNA-Ak, hypocomplementary anaemia, leuko- and thrombocytopenia. Anti-Histon Ak is absent more often.
Indirect immunofluorescenceThis section has been translated automatically.
ANA neg; detection of antimitochondrial antibodies.
General therapyThis section has been translated automatically.
Immediate discontinuation of the medication in question.
Internal therapyThis section has been translated automatically.
Short-term high-dose treatment with a glucocorticoid such as prednisolone (e.g. Solu Decortin 100) 150 mg/day i.v., depending on the clinical condition gradual reduction.
Progression/forecastThis section has been translated automatically.
The disease usually heals within a period of several months after stopping the medication.
LiteratureThis section has been translated automatically.
- Prince JC (2010) Biologics. Dermatologist 61: 668-675